HomeCompareFSTX vs MCD

FSTX vs MCD: Dividend Comparison 2026

FSTX yields 28.09% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FSTX wins by $39.9K in total portfolio value
10 years
FSTX
FSTX
● Live price
28.09%
Share price
$7.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$118.5K
Annual income
$14,804.06
Full FSTX calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — FSTX vs MCD

📍 FSTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFSTXMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FSTX + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FSTX pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FSTX
Annual income on $10K today (after 15% tax)
$2,387.64/yr
After 10yr DRIP, annual income (after tax)
$12,583.45/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, MCD beats the other by $9,710.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FSTX + MCD for your $10,000?

FSTX: 50%MCD: 50%
100% MCD50/50100% FSTX
Portfolio after 10yr
$98.5K
Annual income
$20,515.88/yr
Blended yield
20.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

FSTX
No analyst data
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FSTX buys
0
MCD buys
0
No recent congressional trades found for FSTX or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFSTXMCD
Forward yield28.09%2.35%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$118.5K$78.5K
Annual income after 10y$14,804.06$26,227.70
Total dividends collected$78.8K$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: FSTX vs MCD ($10,000, DRIP)

YearFSTX PortfolioFSTX Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$13,509$2,808.99$10,815$334.85+$2.7KFSTX
2$18,001$3,546.41$11,826$491.71+$6.2KFSTX
3$23,678$4,416.52$13,123$730.06+$10.6KFSTX
4$30,764$5,429.21$14,853$1,100.07+$15.9KFSTX
5$39,510$6,592.67$17,257$1,690.61+$22.3KFSTX
6$50,189$7,913.03$20,752$2,667.01+$29.4KFSTX
7$63,097$9,394.15$26,103$4,354.83+$37.0KFSTX
8$78,551$11,037.47$34,794$7,437.78+$43.8KFSTX
9$96,891$12,841.93$49,926$13,461.60+$47.0KFSTX
10$118,478$14,804.06$78,550$26,227.70+$39.9KFSTX

FSTX vs MCD: Complete Analysis 2026

FSTXStock

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

Full FSTX Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this FSTX vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FSTX vs SCHDFSTX vs JEPIFSTX vs OFSTX vs KOFSTX vs MAINFSTX vs YUMFSTX vs QSRFSTX vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.